BioVectra Inc. Announces Oncolix Inc. Signs Manufacturing and Investment Agreement

CHARLOTTETOWN, PEI--(BUSINESS WIRE)--BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PEI, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for human clinical testing. As part of this agreement, BioVectra will be investing $1.5 million in Oncolix. Prolanta is a targeted therapeutic protein under development for the treatment of breast and ovarian cancer.

Back to news